Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lacticaseibacillus rhamnosus LRa05 + limosilactobacillus reuteri LR08
- Development stage
- Unknown
- Lead developer
- Wecare Probiotics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Vaginal
01
Overview
Lacticaseibacillus rhamnosus LRa05 + Limosilactobacillus reuteri LR08 is a probiotic combination developed by Wecare Probiotics, primarily investigated for its therapeutic potential in women's health. The combination consists of two specific live biotherapeutic strains: *L. rhamnosus* LRa05 and *L. reuteri* LR08. These strains are designed to colonize the vaginal and intestinal mucosa to restore microbial balance. Their mechanism of action involves the production of lactic acid to maintain an acidic environment, the secretion of hydrogen peroxide and bacteriocins to inhibit the growth of pathogens, and competitive exclusion to prevent the adhesion of harmful bacteria and fungi. Clinical studies have focused on the efficacy of this combination in treating and preventing bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC), as well as supporting general gastrointestinal and immune health.
- Other names
- Lactobacillus rhamnosus LRa05 + Lactobacillus reuteri LR08LRa05 + LR08Wecare Probiotics LRa05 + LR08
Beyond the preview
Go deeper on lacticaseibacillus rhamnosus LRa05 + limosilactobacillus reuteri LR08.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lacticaseibacillus rhamnosus LRa05 + limosilactobacillus reuteri LR08.